Phosphatidylinositol 3‐kinase pathway genomic alterations in 60,991 diverse solid tumors informs targeted therapy opportunities
Open Access
- 24 December 2018
- Vol. 125 (7) , 1185-1199
Abstract
Background: The phosphatidylinositol 3‐kinase (PI3K) pathway is frequently altered in cancer. This report describes the landscape of PI3K alterations in solid tumors as well as co‐alterations serving as potential resistance/attenuation mechanisms. Methods: Consecutive samples were analyzed in a commercial Clinical Laboratory Improvement Amendment‐certified laboratory using comprehensive genomic profiling performed by next‐generation sequencing (315 genes). The co‐alterations evaluated included the Erb‐B2 receptor tyrosine kinase 2 ( ERBB2 ), ERBB3 , ERBB4 , RAS , MET proto‐oncogene tyrosine kinase ( MET ), and mitogen‐activated protein kinase kinase ( MAP2K ) genes as well as tumor protein 53 ( TP53 ), estrogen receptor 1 ( ESR1 ), and androgen receptor ( AR). Results: Alterations in any of 18 PI3K‐pathway associated genes were identified in 44% of 60,991 tumors. Although single base and insertions/deletions (indels) were the most frequent alterations, copy number changes and rearrangements were identified in 11% and 0.9% of patients, respectively. Overall, the most frequently altered genes were PIK3 catalytic subunit α ( PIK3CA ) (13%), phosphatase and tensin homolog ( PTEN ) (9%), and serine/threonine kinase 11 ( STK11 ) (5%). Tumor types that frequently harbored at least 1 PI3K alteration were uterine (77%), cervical (62%), anal (59%), and breast (58%) cancers. Alterations also were discerned frequently in tumors with carcinosarcoma (89%) and squamous cell carcinoma (62%) histologies. Tumors with a greater likelihood of co‐occurring PI3K pathway and MAPK pathway alterations included colorectal cancers (odds ratio [OR], 1.64; P < .001), mesotheliomas (OR, 2.67; P = .024), anal cancers (OR, 1.98; P = .03), and nonsquamous head and neck cancers (OR, 2.03; P = .019). The co‐occurrence of ESR1 and/or AR alterations with PI3K alterations was statistically significant in bladder, colorectal, uterine, prostate, and unknown primary cancers. Conclusions: Comprehensive genomic profiling reveals altered PI3K‐related genes in 44% of solid malignancies, including rare disease and histology types. The frequency of alterations and the co‐occurrence of resistance pathways vary by tumor type, directly affecting opportunities for targeted therapy.Keywords
Funding Information
- National Cancer Institute (P30 CA023100)
This publication has 41 references indexed in Scilit:
- Comprehensive Genomic Profiling of Relapsed and Metastatic Adenoid Cystic Carcinomas by Next-generation Sequencing Reveals Potential New Routes to Targeted TherapiesAmerican Journal of Surgical Pathology, 2014
- Assessing PIK3CA and PTEN in Early-Phase Trials with PI3K/AKT/mTOR InhibitorsCell Reports, 2014
- Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencingNature Biotechnology, 2013
- Whole exome sequencing of adenoid cystic carcinomaJournal of Clinical Investigation, 2013
- Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortalScience Signaling, 2013
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics DataCancer Discovery, 2012
- Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimusJournal of Clinical Investigation, 2010
- The PI3K Pathway As Drug Target in Human CancerJournal of Clinical Oncology, 2010
- Targeting PI3K signalling in cancer: opportunities, challenges and limitationsNature Reviews Cancer, 2009
- AKT1E17K in human solid tumoursOncogene, 2008